Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial

[1]  John K Kruschke,et al.  Bayesian data analysis. , 2010, Wiley interdisciplinary reviews. Cognitive science.

[2]  William H. Maisel,et al.  Left atrial appendage occlusion--closure or just the beginning? , 2009, The New England journal of medicine.

[3]  S. Haas.  New anticoagulants - towards the development of an "ideal" anticoagulant. , 2009, VASA. Zeitschrift fur Gefasskrankheiten.

[4]  S. Lerakis,et al.  Left atrial appendage exclusion system for stroke prevention in atrial fibrillation: a percutaneous device delivery approach. , 2008, Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy.

[5]  A. Walker,et al.  Epidemiology and outcomes in patients with atrial fibrillation in the United States. , 2008, Heart rhythm.

[6]  E. Hylek,et al.  Reducing the risk for stroke in patients who have atrial fibrillation. , 2008, Cardiology clinics.

[7]  H. Klemm,et al.  Mechanisms underlying air aspiration in patients undergoing left atrial catheterization , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  S. Yusuf,et al.  Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation , 2007, Circulation.

[9]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[10]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[11]  G. Schuler,et al.  Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[12]  P. Block,et al.  Clinical outcomes three years after PLAATO implantation , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[13]  A. Kalogeropoulos,et al.  Implantation of Left Atrial Appendage Occlusion Devices and Complex Appendage Anatomy: The Importance of Transesophageal Echocardiography , 2007, Echocardiography.

[14]  O. Onalan,et al.  Left Atrial Appendage Exclusion for Stroke Prevention in Patients With Nonrheumatic Atrial Fibrillation , 2007, Stroke.

[15]  D. Sherman.  Stroke Prevention in Atrial Fibrillation: Pharmacological Rate Versus Rhythm Control , 2007, Stroke.

[16]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[17]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[18]  D. Packer,et al.  The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. , 2006, American heart journal.

[19]  Jerry Nedelman,et al.  Book review: “Bayesian Data Analysis,” Second Edition by A. Gelman, J.B. Carlin, H.S. Stern, and D.B. Rubin Chapman & Hall/CRC, 2004 , 2005, Comput. Stat..

[20]  E. Kaufman,et al.  Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. , 2005, Archives of internal medicine.

[21]  H. Ashraf.  Anticoagulation therapy for stroke. , 2005, Drug discovery today.

[22]  P. Teirstein,et al.  Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. , 2005, Journal of the American College of Cardiology.

[23]  Palle Petersen,et al.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.

[24]  G. Albers.  Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. , 2004, The American journal of managed care.

[25]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[26]  D. Levy,et al.  Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.

[27]  Randolph P. Martin,et al.  Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. , 2004, Journal of the American College of Cardiology.

[28]  J. Finsterer,et al.  Elimination of the left atrial appendage to prevent stroke or embolism? Anatomic, physiologic, and pathophysiologic considerations. , 2003, Chest.

[29]  Yuchiao Chang,et al.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.

[30]  S. Olsson,et al.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.

[31]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[32]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[33]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[34]  M. Lesh,et al.  Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: Early Clinical Experience , 2002, Circulation.

[35]  Ana Ruigómez,et al.  Incidence of chronic atrial fibrillation in general practice and its treatment pattern. , 2002, Journal of clinical epidemiology.

[36]  J. Coste,et al.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. , 2001, The New England journal of medicine.

[37]  J. McMurray,et al.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study , 2001, Heart.

[38]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[39]  M. Rich,et al.  Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. , 2000, Stroke.

[40]  D. Singer,et al.  Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.

[41]  L H Kuller,et al.  Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.

[42]  Strokepreventioninatrialfibri.  The stroke prevention in atrial fibrillation III study: rationale, design, and patient features. , 1997, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[43]  R B D'Agostino,et al.  Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.

[44]  J. Odell,et al.  Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.

[45]  P. Koudstaal.  Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. , 1995, The New England journal of medicine.

[46]  N. Ammash,et al.  Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographics tudy , 1995 .

[47]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[48]  H. White,et al.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .

[49]  M. Ezekowitz,et al.  Stroke Prevention in Atrial Fibrillation II Study. , 1994, Lancet.

[50]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[51]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[52]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[53]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[54]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[55]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[56]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[57]  D. Anderson.  Progress report of the Stroke Prevention in Atrial Fibrillation Study. , 1990, Stroke.

[58]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[59]  Z. J. Lipowski.  Letter: Psychosomatic medicine. , 1974, Lancet.

[60]  H. Aberg.  Atrial fibrillation. I. A study of atrial thrombosis and systemic embolism in a necropsy material. , 2009, Acta medica Scandinavica.